Cellular Screening in 2D and 3D  – Identification of cancer specific modulators by Ellinger, Bernhard
Cellular Screening in 2D and 3D 
–
Identification of cancer specific 
modulators
ELRIG.de, March 2013
Introduction
• International FP7 program
• Aim is the identification of novel compounds with anti-cancer properties from 
marine fungi
• Work packages include: isolation, fermentation and screening of marine fungi 
extracts and compounds
Marine natural products
Source Extracts Organisms No. hits Hit Rate (%)
Mediterranean sponge fungi 754 206 78 10.3
Chilean macro-algal fungi 125 125 48 38.4
Indonesian coral fungi 331 105 47 16.5
Totals 1210 436 173 14.3
• Hypha Discoveries Stimulation Fermentation technology gave rise to 1210 
crude extracts from 600 fungal strains
• Bioactivity guided fractionation was used to identify individual active fractions. 
• 78 pure (> 80% by weight) active natural product compounds were then 
obtained following strain re-fermentation, induction, isolation and purification. 
• Compound structures were elucidated using NMR 
Assay principle
Tissue origin No. of 
cell lines
Leukemia 6
Non-Small Cell Lung 9
Colon 7
• Recording of cytotoxicity profiles of the 
fungal extracts and compounds
• Obtain GI50, TGI and LC50 in the whole 
NCI 60 panel 
Concentration at:
• 50% cell growth = GI50 
• 0% cell growth = TGI
• -50% cell growth = LC50
CNS 6
Melanoma 9
Ovarian 7
Renal 8
Prostate 2
Breast 6
NCI 60 panel
Measurement procedure
Cell seeding and incubation for
24h
Compound addition Detection of viability at day 0, is
set to 0% growth
Day 0
Day 1
Detection of viability
Incubation for 48h in the
presence of compoundDay 2
Day 3
• Cytostatic and cytotoxic 
compounds can be identified
• In accordance to NIH criteria
Assay development
• RPMI1640 supplemented with 10% FCS and 2mM L-Glutamine 
• doubling time between 18 and 80h
• NCI assay protocol includes 96 well plates, 200µl assay volume and a 
staining protocol
• current protocol includes 384 well plates, 25µl assay volume and ATP 
determination using CellTiter-Glo (Promega)
Assay development
• Assay development includes: cell titration, DMSO tolerance and standard 
compounds (Cisplatin, Paclitaxel, 6-Mercaptopurine, Staurosporine)
• Luciferase counter assay has to be performed for all tested compounds
• Cisplatin inhibits luciferase at a concentration of 100µM
Physiological relevance of NCI60 panel –
kinase inhibitors
• RH004 selective kinase inhibitor against VEGFR2
• RPMI-8226 cells do express VEGFR2
• RH007 selective kinase inhibitor against V600E BRAF-mutation
• only the M14 cell lines has this mutation
• Mean values and deviation from 
the means has to be calculated
• All data have to be transformed 
to be uploaded to the NCI 
COMPARE database
• Output is a likelihood analysis of 
similar compounds and involved 
pathways 
• Data is shared within the 
Physiological relevance of NCI60 panel –
COMPARE algorithm
NCI mean graph analysis
consortia by an encrypted web 
portal 
Correlation
of test 
compounds 
to database
Output
NCI
Mean
graph
COMPARE
online tool
GI50,
TGI,
LC50
Data MoA
studies
Target 
directed
studies
Rank Compound Common cell lines Description of mode of action
1 glycoxalic acid 30 natural exfoliant
2 asaley 25 alkylates and crosslinks DNA
3 methyl-CCNU 29 alkylates and crosslinks DNA
4 AZQ 28 alkylates and crosslinks DNA
Physiological relevance of NCI60 panel –
COMPARE algorithm
• Cisplatin data from 30 cell lines were used to perform a COMPARE analysis
• Cisplatin was found within the top 5
• 18 of the top25 alkylate or crosslink DNA
5 cisplatin 30 crosslinks DNA
Automatisation of the cell culture processes 
SF-593 A549-ATCC
M14 786-0
The bead –
the core of the technology
Brand name Specification
GEM Dextran beads with iron particles
for magnetic separation
Cytodex 1 Dextran beads with positive-
charged DEAE groups throughout 
matrix
Cytodex 3 Dextran beads coated with 
denatured porcine-skin collagen 
bound to surface.
Cell line Tissue type Bead type
M14 Melanoma Cytodex 3
786-0 Renal GEM or Cytodex 1
A549/ATCC Non-Small Cell Lung Cytodex 1
SF-539 CNS Cytodex 1
scheme of a bead
Optimisation –
cell number
cell seeding
1x106 cells in 
25 ml media
• Doubling times between 18 to 80 hours
• Bead coating is also critical for growth
72h48h24h
6h
addition of 
25 ml media
Optimisation –
counting
Measurement 
by Millipore 
10 min wash; add trypsin resuspend1 vol. 10% dextranase 10 min
Scepter 
• Direct addition of trypsin to the beads not possible
• Dextranase has to be removed before trypsin addition
Optimisation –
known drugs
• 4 known compounds used for 
comparison of 2D and 3D 
• Reference compounds for HTS 
screening
GI50 TGI LC50
Cisplatin
M14
2D 10 15.00 20
3D 22 30.81 42
A549-
ATCC
2D 31 42.85 60
3D 13 20.45 34
M14
2D 0.2 0.4 0.8
1 – 1.5
1.5 – 2.5
> 2.5
Fold difference
Data from 3D experiment using A549-ATCC 
Paclitacel
3D NA 0.7 2
A549-
ATCC
2D 0.06 0.1 NA
3D NA 0.3 0.9
Screening in 2D and 3D
• 241 compounds of marine 
origin were screened in 2D 
and 3D
• R2 = 0.95
• 50 µM compound 
concentration, single point
•Known drug: 5 mM cisplatin
compound
known drug
DMSO only
emtpy well
Dose-Response curves
3D –
GI50
2D –
GI50
3D –
TGI
2D –
TGI
3D –
LC50
2D –
LC50
compound 1 62.4 69.1 80.6 86.6 93.8 100.6
compound 2 74.5 97.4 87.2 98.7 96.8 99.7
compound 3 85.8 87.5 92.8 93.3 97.3 97.3
compound 4 28.4 22 59.5 52.9 107.5 99.6
compound 5 86.7 88.3 98 98.6 111.3 105.9
• 56 dose response curves 
where recorded
• No significant differences 
are observed
• 3D data confirm 2D 
experiments
0 – 5
5 - 10
> 10
All data in µM
compound 6 84.9 69 92.8 86.8 97.7 101.5
compound 7 88.2 71.2 96.3 89.7 100.9 114.9
compound 8 64.2 56.7 84.8 80.6 100.6 99.8
compound 9 83.1 84.8 89.8 91.2 95.1 95.9
compound 10 89 85 97.9 95 103.4 101.4
compound 11 100.5 93 109.5 107.1 115.1 115.1
compound 12 97.2 94.4 101.9 105.8 105.1 113.2
Difference 
in percent
Automatisation of the measurement processes 
Confluence analysis using Cell Metric 
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• A549-ATCC cell line shown
• analysis done by Cell Metric from Solentim
• non-invasive measurement enables the 
recurrent analysis of a single plate
• no additional day 0 plate necessary
Confluence and viability analysis
• Two measurements necessary for live/dead analysis
• Fast confluence analysis, image stacks to identify dead cells (diffraction 
index and roundness)
• 5 min per plate
brightfield whole cell analysis live/dead analysis composite image
Analysis of standard compounds
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Cell Metrics ViaConfluence Cisplatin 
SK-Mel-5
Cell Metrics Confluence CisplatinSK-Mel-5
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Cell Metrics ViaConfluence 
Paclitaxel SK-Mel-5
Cell Metrics Confluence 
Paclitaxel SK-Mel-5
Cisplatin analysis
Paclitaxel analysis
• SK-MEL5 cell line shown
• Viabibilty analysis 
performs superion over 
confluence analysis
• good comparison in the 
case Cisplatin
• discrepansies in the case 
of Paclitaxel/Taxol
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